* OptimizeRx Corp reported quarterly adjusted earnings of 12 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 9 cents. The mean expectation of eight analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from 1 cents to 10 cents per share.
* Revenue rose 30.5% to $21.31 million from a year ago; analysts expected $25.00 million.
* OptimizeRx Corp's reported EPS for the quarter was a loss of 50 cents.
* The company reported a quarterly loss of $9.12 million.
* OptimizeRx Corp shares had fallen by 24.4% this quarter and lost 59.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 5.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the online services peer group is also "buy"
Wall Street's median 12-month price target for OptimizeRx Corp is $11.50 This summary was machine generated from LSEG data November 14 at 04:16 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.06 0.12 Beat
Jun. 30 2024 -0.06 0.02 Beat
Mar. 31 2024 -0.13 -0.11 Beat
Dec. 31 2023 0.32 0.26 Missed
Comments